Company profile

Incorporated in
Fiscal year end
IRS number


31 Oct 19
7 Dec 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Sep 19 Jun 19 Mar 19 Dec 18
Revenue 6.01B 6.27B 5.92B 5.97B
Net income 1.35B 1.43B 1.71B 1.16B
Diluted EPS 0.83 0.87 1.04 0.71
Net profit margin 22.52% 22.83% 28.89% 19.42%
Net change in cash 2.09B 21.07B 424M 1.5B
Cash on hand 30.49B 28.4B 7.34B 6.91B
Cost of revenue 1.81B 1.99B 1.84B 1.69B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 22.56B 20.78B 19.43B 16.56B
Net income 4.92B 1.01B 4.46B 1.57B
Diluted EPS 3.01 0.61 2.65 0.93
Net profit margin 21.81% 4.85% 22.94% 9.45%
Net change in cash 1.49B 1.18B 1.85B -3.19B
Cash on hand 6.91B 5.42B 4.24B 2.39B
Cost of revenue 6.55B 6.09B 4.97B 3.91B

Financial data from company earnings reports

Financial report summary

Management Discussion
  • U.S. revenues increased due to higher demand for Eliquis and Orencia in both periods and for Opdivo in the nine months ended September 30, 2019, partially offset by declines in established brands. The lower growth rate in the three months period compared to the nine month period was primarily due to Opdivo and Yervoy trends and higher Medicare Part D coverage gap cost share (from 50% in 2018 to 70% in 2019). Average net selling prices after discounts, charge-backs and rebates were 2% lower in the third quarter 2019 and 1% higher year-to-date and are expected to be roughly flat on a full year basis.
  • Europe revenues increased in both periods due to higher demand for Eliquis and Opdivo, partially offset by foreign exchange, lower demand for established brands and lower average net selling prices.
  • Rest of the World revenues increased in both periods due to higher demand for Opdivo, Eliquis and Yervoy, partially offset by foreign exchange.
Content analysis ?
H.S. freshman Avg
New words: alternative, Amgen, antagonist, bempegaldesleukin, Breakthrough, bring, Cardiology, care, committee, compliance, complied, concomitantly, CVR, Director, doublet, ESCC, imposed, irrevocably, lapse, maintenance, merit, moved, NaN, negotiated, nonvalvular, OAC, OS, proceed, profile, raw, regimen, SAS, smaller, sooner, successful, therefrom, trend, unconditional
Removed: anticoagulant, constructing, Corporation, dollar, Incyte, misappropriation, newer, prejudice, private, sued, ultimate, vigorously